Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$5.77
+7.1%
$5.37
$2.94
$10.25
$326.18M3.0578,611 shs110,354 shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$23.05
+4.9%
$21.37
$11.51
$26.33
$1.21B-2.8112,678 shs259,519 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$12.22
+5.7%
$9.71
$6.50
$18.98
$1.30B0.83717,262 shs1.10 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$15.05
+6.9%
$13.63
$9.03
$17.70
$1.13B1.27528,693 shs627,107 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
+7.05%+14.03%+17.76%+29.37%-27.60%
Pharvaris N.V. stock logo
PHVS
Pharvaris
+4.87%+6.47%+8.57%+37.37%+33.16%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+5.61%+15.34%+28.84%+22.26%-25.12%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+6.89%+1.62%+21.27%+19.44%+29.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$5.77
+7.1%
$5.37
$2.94
$10.25
$326.18M3.0578,611 shs110,354 shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$23.05
+4.9%
$21.37
$11.51
$26.33
$1.21B-2.8112,678 shs259,519 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$12.22
+5.7%
$9.71
$6.50
$18.98
$1.30B0.83717,262 shs1.10 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$15.05
+6.9%
$13.63
$9.03
$17.70
$1.13B1.27528,693 shs627,107 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
+7.05%+14.03%+17.76%+29.37%-27.60%
Pharvaris N.V. stock logo
PHVS
Pharvaris
+4.87%+6.47%+8.57%+37.37%+33.16%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+5.61%+15.34%+28.84%+22.26%-25.12%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+6.89%+1.62%+21.27%+19.44%+29.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3.17
Buy$10.6784.86% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
2.80
Moderate Buy$34.0047.51% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.75
Moderate Buy$21.1473.02% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.4342.38% Upside

Current Analyst Ratings Breakdown

Latest FHTX, PHVS, RCUS, and ZYME Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/13/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$55.00 ➝ $52.00
8/11/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$19.00 ➝ $22.00
8/7/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$26.00 ➝ $25.00
7/3/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$13.00
6/11/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$32.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$22.60M14.43N/AN/A($0.82) per share-7.04
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$5.54 per shareN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$258M5.04N/AN/A$5.30 per share2.31
Zymeworks Inc. stock logo
ZYME
Zymeworks
$122.87M9.21N/AN/A$6.63 per share2.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$86.62M-$1.19N/AN/AN/A-311.90%N/A-28.00%11/3/2025 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)

Latest FHTX, PHVS, RCUS, and ZYME Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.87-$0.94-$0.07-$0.94N/AN/A
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52$0.03+$0.55N/A$17.18 million$48.73 million
8/6/2025Q2 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 million
8/5/2025Q2 2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$0.31-$0.28+$0.03-$0.28$7.62 million$7.56 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/A
2.62
2.62
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
8.33
8.33
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.18
4.50
4.50
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
61.55%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
7.58%
Pharvaris N.V. stock logo
PHVS
Pharvaris
11.84%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
12056.53 million52.25 millionOptionable
Pharvaris N.V. stock logo
PHVS
Pharvaris
3052.29 million46.10 millionNot Optionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500106.43 million96.21 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46075.17 million67.56 millionOptionable

Recent News About These Companies

Bloom Burton Comments on Zymeworks FY2025 Earnings
Zymeworks (NYSE:ZYME) Shares Gap Down - What's Next?
Zymeworks Inc. $ZYME Stake Reduced by Redmile Group LLC
Zymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LP
Health Sector Innovations: From Blood Thinners to Bird Flu Outbreaks
Zymeworks Reports Q2 Results and FDA Clearance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Foghorn Therapeutics stock logo

Foghorn Therapeutics NASDAQ:FHTX

$5.77 +0.38 (+7.05%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$5.78 +0.01 (+0.09%)
As of 09/5/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$23.05 +1.07 (+4.87%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$23.10 +0.04 (+0.20%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$12.22 +0.66 (+5.71%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$12.21 -0.01 (-0.08%)
As of 09/5/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$15.05 +0.97 (+6.89%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$15.18 +0.13 (+0.83%)
As of 09/5/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.